|
|
| Decode the shift. Accelerate approvals. | New FDA flexibility can accelerate your timeline or derail it. The difference is in how you apply it. With fewer comparability requirements and more adaptive CMC pathways, sponsors have new opportunities to move faster, but only with the right strategy. This expert analysis breaks down what matters, helping you strengthen manufacturing, and mitigate compliance risks. Don't just adapt to change. Capitalize on it.
Get the regulatory roadmap. |
|
|
|
|
By Life Science Connect Editorial Staff | Scaling iPSC-based therapies from lab to CGMP manufacturing demands tightly controlled cryopreservation, risk-based QC, and strategic automation to preserve cell viability, consistency, and regulatory readiness. | |
|
|
| Transforming Clinical Trial Management | Case Study | McCreadie Group | Discover how a digital-first approach can simplify operations, reduce risk, streamline workflows, strengthen compliance, and eliminate inefficiencies through a smarter, digital-first approach. |
|
|
|
|
|
|
|
|
| Join Cell & Gene Live for an expert discussion on choosing the right manufacturing model for CGT pipelines. Industry leaders will examine centralized, decentralized, and hybrid approaches, sharing practical frameworks, operating models, and key tradeoffs affecting scalability, cost, timelines, and patient access. Featuring insights from Erin Harris, Omkar Kawalekar, and Zoe Zheng. Click here to learn more. |
|
|
CLINICAL TRIALS SOLUTIONS |
|
|
|
|
|
|
|
| Connect With Cell & Gene: |
|
|
|
